AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Launched by ASTRAZENECA · Mar 28, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called AZD0901 for patients with advanced or metastatic gastric cancer or gastroesophageal junction cancer that expresses a specific protein known as Claudin18.2. The goal is to see how effective and safe AZD0901 is compared to other treatments chosen by doctors for patients who have already received at least one type of therapy. If you're at least 18 years old, have been diagnosed with this type of cancer, and have shown disease progression despite previous treatments, you might be eligible to participate.

Participants can expect to be closely monitored throughout the trial to assess how well the treatment works and to check for any side effects. To join, you will need to provide informed consent and meet certain health criteria, such as having a good performance status and adequate organ function. It's important to know that some conditions, like active brain problems or certain types of eye disease, may exclude you from the study. Overall, this trial aims to find better treatment options for patients battling this challenging disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Capable of giving signed informed consent prior to any study procedure.
• • 2. Participant must be at least 18 years or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the ICF.
• 3. Histologically confirmed unresectable, locally advanced or metastatic adenocarcinoma of gastric, GEJ, or distal esophagus (distal third of the esophagus) and the following requirement:
• • (a) Participants with positive CLDN18.2 expression from archival tumor collected within past 24 months or from a fresh biopsy.
• • 4. Disease progression on or after at least one prior line of treatment (LoT) for advanced or metastatic disease, which included a fluoropyrimidine and a platinum, for advanced or metastatic disease.
• • 5. Must have at least one measurable or evaluable lesion assessed by the Investigator based on RECIST 1.1.
• • 6. ECOG performance status of 0 or 1 with no deterioration over the previous 2 weeks prior to baseline or day of first dosing.
• • 7. Predicted life expectancy of ≥ 12 weeks.
• • 8. Adequate organ and bone marrow function
• • 9. Body weight of ≥ 35 kg.
• • 10. Sex and Contraceptive Requirements
• Exclusion Criteria:
• • 1. Participants with known HER2 positive status as defined as IHC 3+ or IHC 2+/ISH + (Cases with HER2: CEP17 ratio ≥ 2 or an average HER2 copy number ≥ 6.0 signals/cell are considered positive by ISH). Participants must undergo local (or have had) HER2 testing by IHC/ISH, and the most recent result of HER2 status will be used to determine the eligibility.
• • 2. Participant has significant or unstable gastric bleeding and/or untreated gastric ulcers.
• • 3. CNS metastases or CNS pathology including: epilepsy, seizures or aphasia within 3 months prior to consent, severe brain injury, dementia, Parkinson's disease, neurodegenerative diseases, cerebellar disease, severe uncontrolled mental illness, psychosis, CNS involvement of autoimmune diseases.
• • 4. Participant has known clinically significant corneal disease (eg, active keratitis or corneal ulcerations).
• • 5. Persistent toxicities (CTCAE Grade ≥ 2) caused by previous anticancer therapy, excluding alopecia. Participants with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention may be included (eg, hearing loss).
• • 6. Prior exposure to any ADC with MMAE payload or any CLDN18.2 targeting treatment other than naked monoclonal antibody (eg, CLDN18.2 targeting CAR-T cell therapy, multi-specific antibody including targeting CLDN18.2, etc).
• 7. History of thromboembolic events:
• • 1. Participants with venous thromboembolism within the past 6 months prior to randomization: participants with venous port or catheter thrombosis or superficial venous thrombus that do not require treatment or are stable on treatment with anticoagulants are excepted
• • 2. History of arterial thromboembolism within the past 12 months prior to randomization
• • 8. As judged by the Investigator, any evidence of diseases which in the Investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol.